Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
D 107.73 -0.32% -0.35
ABBV closed down 0.32 percent on Friday, September 17, 2021, on 1.8 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Flat
Historical ABBV trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Boomer Sell Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Inside Day Range Contraction -0.32%
Oversold Stochastic Weakness -0.32%
Outside Day Range Expansion -0.04%
Older End-of-Day Signals for ABBV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


AbbVie Inc. Description

AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Acid Pharmaceutical Products Autoimmune Diseases Chemical Compounds Organic Compounds Prostate Cancer Autoimmune Disease Distribution Center Thyroid Cardiology Cholesterol Anesthesia Respiratory Disease Chloroarenes Testosterone Gabaa Receptor Positive Allosteric Modulators Triglyceride Carbidopa Hyperparathyroidism Low Density Lipoprotein Advanced Prostate Cancer Niacin Secondary Hyperparathyroidism Anesthesia Product Celiac Celiac Disease Exocrine Pancreatic Insufficiency Hypothyroidism Lipoproteins Research Based Biopharmaceutical Testosterone Replacement Therapy

Is ABBV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 121.5
52 Week Low 79.11
Average Volume 6,782,435
200-Day Moving Average 110.87
50-Day Moving Average 115.37
20-Day Moving Average 113.32
10-Day Moving Average 108.24
Average True Range 2.41
ADX 39.64
+DI 9.93
-DI 32.83
Chandelier Exit (Long, 3 ATRs) 114.27
Chandelier Exit (Short, 3 ATRs) 113.26
Upper Bollinger Bands 124.62
Lower Bollinger Band 102.01
Percent B (%b) 0.25
BandWidth 19.96
MACD Line -2.66
MACD Signal Line -2.05
MACD Histogram -0.6148
Fundamentals Value
Market Cap 190.19 Billion
Num Shares 1.77 Billion
EPS 4.57
Price-to-Earnings (P/E) Ratio 23.56
Price-to-Sales 4.13
Price-to-Book 12.13
PEG Ratio 1.28
Dividend 5.20
Dividend Yield 4.83%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 109.45
Resistance 3 (R3) 109.43 108.84 109.16
Resistance 2 (R2) 108.84 108.40 108.85 109.07
Resistance 1 (R1) 108.29 108.13 108.56 108.30 108.97
Pivot Point 107.69 107.69 107.83 107.70 107.69
Support 1 (S1) 107.14 107.26 107.42 107.16 106.49
Support 2 (S2) 106.55 106.99 106.56 106.39
Support 3 (S3) 105.99 106.55 106.30
Support 4 (S4) 106.01